| Name | Title | Contact Details |
|---|
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for five additional years of QIDP market exclusivity in the event of U.S. approval. It is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.
AnaSpec, EGT Group is a leading provider of integrated proteomics and genomics solution for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and qPCR. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis.
Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles.
Klox Technologies is a Canadian specialty pharmaceutical company focusing on the development and commercialization of its proprietary BioPhotonic technology platform. This non-invasive, pathology-specific topical treatment platform harnesses the power of light and photo activated oxygen-rich gel formulations to target various skin and soft tissue disorders. With franchises in dermatology, wound care, and oral health, Klox Technologies is well positioned to capitalize on significant market opportunities. We believe that our dedication to providing healthcare professionals with novel and effective treatment solutions will allow patients to experience positive results without some of the side effects associated with existing treatments. Klox Technologies’ senior management team has over 80 years of combined experience in the biotechnology, pharmaceutical, and medical devices industries. We continue to research, develop, and commercialize solutions based on our BioPhotonic technology platform for a growing and aging population that is seeking more effective and less invasive treatment options to improve their health and quality of life.
Elco Laboratories Inc is a University Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.